Skip to main content

Table 4 Total ambulatory care expenditures according to time and treatment phase for patients (€)

From: Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France

 

2005

  

2006

  

2007

  

2008

  

2009

  

2010

  

N

Mean

SD

N

Mean

SD

N

Mean

SD

N

Mean

SD

N

Mean

SD

N

Mean

SD

Patients with Normal Renal Function

Monotherapy

5,507

2,703

3,333

5,543

2,711

3,407

5,682

2,821

3,542

5,921

2,971

3,916

5,538

2,980

3,876

4,353

3,017

3,829

Double therapy

2,324

2,884

3,113

2,587

2,935

3,206

2,762

3,095

3,622

2,839

3,125

3,611

2,786

3,171

3,861

2,503

3,308

4,045

Triple therapy

328

3,473

3,121

406

3,295

3,013

505

3,313

2,938

587

3,180

3,011

658

3,264

3,312

728

3,609

3,801

Insulin therapy

898

6,759

5,203

1,029

6,800

5,192

1,150

7,063

5,573

1,214

7,058

5,903

1,256

7,228

5,658

1,032

7,398

5,487

Non diabetic patients

27,389

1,715

2,914

28,962

1,767

3,060

30,618

1,866

3,261

32,103

1,994

3,475

31,128

2,150

3,979

26,253

2,166

4,102

Patients with Declining Renal Function

Monotherapy

282

4,148

4,258

339

4,267

4,426

393

4,396

4,811

465

4,897

6,427

518

4,149

4,637

411

4,226

5,369

Double therapy

157

3,773

3,144

228

3,603

3,628

266

3,667

3,257

308

3,892

4,004

310

3,891

4,623

267

4,159

5,268

Triple therapy

27

4,244

3,641

41

3,105

1,617

45

4,052

3,396

69

4,203

4,411

71

3,387

3,027

78

4,032

4,329

Insulin therapy

136

10,772

9,335

188

10,227

8,882

240

10,644

10,731

294

10,499

10,185

359

11,155

11,188

267

11,344

11,185